Buradasınız

Birinci basamakta erişkin astım yönetimi

Adult asthma management in primary care

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Asthma is currently one of the world’s most common long-term conditions; the disease may affect as many as 300 million people worldwide, a number that could increase further by another 100 million by the year 2025. The increasing prevalence of asthma, frequency of hospital admission and asthma related mortality have led to a great concern about the medical and social costs of this disease. The common denominator underlying the pathogenesis of asthma is bronchial hyperresponsiveness and atopy is the commonest risk factor for asthma development; others are air pollution, respiratory infection, obesity, family size, occupation, as well as tobacco smoking and drugs. In this review; it is aimed to raise awareness of family physicians about asthma by emphasizing on asthma management and treatment accompanied by new guidelines.
Abstract (Original Language): 
Astım, günümüzde dünyadaki en yaygın ve uzun süreli takip gerektiren durumlardan biridir; dünya çapında 300 milyon kişinin etkilendiği; bunun 2025 yılı civarı 100 milyon daha artabileceği öngörülmektedir. Artan astım prevalansı, hastane başvuru sıklığı ve astıma bağlı mortalite, hastalığın medikal ve sosyal maliyeti üzerine eğinilmesine yol açmıştır. Astım patogenezinin altında yatan en önemli nedenler olan bronşiyal hiperreaktivite ve atopi, astım gelişimindeki en yaygın risk faktörleri olup diğerleri; hava kirliliği, solunum yolu enfeksiyonu, obezite, aile yapısı, meslek, tütün ve ilaç kullanımıdır. Bu makalede astım yönetimi ve tedavisi üzerinde durularak yeni klavuzlar eşliğinde aile hekimlerinin astım hakkındaki farkındalıklarının artırılması amaçlanmıştır.
39-44

REFERENCES

References: 

1. Global Initiative for Asthma (GINA). Global strategy
for asthma management and prevention. Updated
2011. [http://www.ginaasthma.org.] adresinden
13/01/2012 tarihinde erişilmiştir.
2. Türk Toraks Derneği Astım Tanı ve Tedavi Rehberi.
2010; 11(1):6-74.
3. Devereux G, Seaton A. Diet as a risk factor for atopy
and asthma. J Allergy Clin Immunol 2005; 115:1109-
1017.
4. Demir AU, Karakaya G, Bozkurt B, Sekerel BE,
Kalyoncu AF. Asthma and allergic disease in
schoolchildren: third cross-sectional survey in the
same primary school in Ankara, Turkey. Pediatr
Allergy Immunol 2004; 15(6):531-538.
5. Holgate S. Pathogenesis of Asthma. Clin Exp Allergy
2008; 38(6):872-897.
6. Çelikel S, Karakay G. Astım. Solunum
Hastalıkları’nda. Ed. Çöplü L, Kaya A. Ankara,
Poyraz Tıbbi Yayıncılık San. ve Tic. Ltd. Şti., 2007;
74-87.
7. Kaplan AG, Balter MS, Bell AD, Kim H, Mclvor RA.
Diagnosis of asthma in adults. Canadian Medical
Association Journal 2009; 181:210-220.
8. British Thoracic Society Scottish Interollegiate
Guidelines Network. British Guideline on the
management of Asthma. Thorax 2008; 63:1-121.
9. Boulet LP. Approach to adults with asthma.
Middleton’s Allergy. Ed. Adkinson F, Bochner BS,
Busse WW, Holgate ST, Lemanske RF, Simons FER.
Seventh Edition. Philadelphia, Elsevier Inc. 2009;
1346-1363.
10. Kilian KJ, Watson R, Otis J, St Amand TA, O’Byrne
PM. Symptom perception during acute
bronchoconstriction. Am J Respir Crit Care Med
2000; 162(2 Pt 1):490-496.
11. Rodrigo GJ, Rodrigo C, Hall JB. Acute Asthma in
Adults: A review. Chest 2004; 125:1081-1102.
12. Daman HR. Pulmonary function testing: use of the
peak expiratory flow rate in an out-patient or office
setting. J Asthma 1984; 21:331-337.
13. Connolly CK, Chan NS. Relationship between
different measurements of respiratory function in
asthma. Respiration 1987; 52:22-33.
14. Meltzer AA, Smolensky MH, D’Alonzo GE, Harrist
RB, Scott PH. An assessment of peak expiratory flow
as a surrogate measurement of FEV1 in stable
asthmatic children. Chest 1989; 96:329-333.
15. Paggiaro PL, Moscato G, Giannini D, Di Franco A,
Gherson G. Relationship between peak expiratory
flow (PEF) and FEV1. Eur Respir J 1997; 10(Suppl
24):39-41.
16. Süerdem M. Astım ve KOAH: Tanım, Epidemiyoloji
ve Tanı. Astım ve KOAH’da İnhalasyon Tedavisi
(TÜSAD Eğitim Kitapları Serisi). Ed. Öztürk C,
Çalışkaner AZ. 1. Baskı. İstanbul, Deomed Medical
Yayıncılık, 2009; 7-18.
17. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos
F, Casaburi R, et al. Interpretative strategies for lung
function tests. Eur Respir F 2005; 26(5):948-968.
18. Expert Panel Report 3 (EPR-3): Guidlines for the
diagnosis and management of asthma- Full Report
2007. J Allergy Clin Immunol 2007; 120:94-138.
19. British Guideline on the Management of Asthma. A
national clinical guideline British Thoracic Society
Scottish Intercollegiate Guidelines Network. Revised
edition 2011. [http://www.britthoracic.
org.uk/Portals/0/Guidelines/Asthma
Guidelines/sign101 Sept 2011.pdf] adresinden
02.02.2012 tarihinde erişilmiştir.
20. Pizichini MM, Popov TA, Efthimiadis A, Hussack P,
Evans S, Pizichini E, et al. Spontaneous and induced
sputum to measure indices of airway inflamation in
asthma. Am J Respir Crit Care Med 1996; 154(4 Pt
1):866-869.
21. Kharitonov S, Alving K, Barnes PJ. Exhaled nitric
oxide measurements: recommendations. The European
Respiratory Soociety Task Force. Eur Respir J 1997;
10(7):1683-1693.
22. Horvath I, Hunt J, Barnes PJ, Alving K, Antcak A,
Baraldi E, et al. Exhaled breath condensate:
methodological recommendations and unresolved
questions. Eur Respi J 2005; 26:523-548.
23. Bateman ED, Boushey HA, Bousquet J, Busse WW,
Clerk TJ, Pederson SE. The correlation between
asthma control and health status: the GOAL study. Eur
Respir J 2007; 29:56-62.
24. Global Initiative for Asthma (GINA). Global strategy
for asthma management and prevention; Pocket guide
for asthma management and prevention; for adults and
children older than 5 years; Updated 2011)
[http://www.ginasthma.org/guidelines-pocket-guidefor-
asthma-management.html] adresinden 13/01/2012
tarihinde erişilmiştir.
25. Wenzel S. Severe Asthma in adults. Am J Respir Crit
Care Med 2005; 172(2):149-160.
İletişim:
Uzm. Dr. Adem Parlak
Ağrı Asker Hastanesi
Birinci Basamak Muayene ve Aile Sağlığı Merkezi
Ağrı, Türkiye
tel: +90.532.7086899
e-mail: adem_par@yahoo.com.tr

Thank you for copying data from http://www.arastirmax.com